Ono Pharmaceutical Co Ltd 2016 IR
The report highlights ONO PHARMACEUTICAL's financial and non-financial performance for the fiscal year ended March 31, 2016. Key achievements include the expanded sales and additional indications of the breakthrough anticancer drug OPDIVO in Japan, the US, and Europe. The company completed a new research building at the Minase Research Institute to integrate compound synthesis and analysis functions. ONO also advanced its CSR management by identifying six priority areas aligned with ISO 26000 and made progress in reducing its environmental impact, achieving a 17.2% reduction in CO2 emissions from production and research sites compared to FY2005.
Company: Ono Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2016
Type: IR
Pages: 124
Ono Pharmaceutical Co Ltd
Corporate Report
The report highlights ONO PHARMACEUTICAL's financial and non-financial performance for the fiscal year ended March 31, 2016. Key achievements include the expanded sales and additional indications of the breakthrough anticancer drug OPDIVO in Japan, the US, and Europe. The company completed a new research building at the Minase Research Institute to integrate compound synthesis and analysis functions. ONO also advanced its CSR management by identifying six priority areas aligned with ISO 26000 and made progress in reducing its environmental impact, achieving a 17.2% reduction in CO2 emissions from production and research sites compared to FY2005.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Apr 1, 2015 - Mar 31, 2016
Fiscal Year
2015
Published
Aug 1, 2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees